Southern Illinois University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Southern Illinois University sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Southern Illinois University: 21 sponsored US clinical trials, 2 recruiting.
Southern Illinois University sponsors 21 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 14 completed. 3 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Raynaud's Disease, with 1 trials.
Top-decile sponsor footprint
Southern Illinois University ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
Oral Iron Supplementation on Alternate Vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy
NCT06492512
Rural Illinois Lung Cancer Screening Initiative
NCT06084078
Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass
NCT02109367
Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
NCT03682224
MK-3475/BCG in High Risk Superficial Bladder Cancer
NCT02324582
Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses
NCT02690415
Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
NCT02462837
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
NCT02410135
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
NCT02324439
Vascularized Composite Allotransplantation of the Hand and Upper Extremity (Hand Transplant)
NCT02165865
Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)
NCT02903355
Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer
NCT01587820
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
NCT01771653
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
NCT01309802
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
NCT01128218
Burn Micronutrient Repletion Pilot Study
NCT00879723
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
NCT01111942
Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients
NCT00728130
A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer
NCT00631852
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
NCT00304278
Effectiveness of the American Lung Association Reactive Anti-Smoking Telephone Help Line in Illinois
NCT00749151
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Southern Illinois University pipeline
2 recruiting of 21 indexed (10% open); 14 completed (67%).
Phase mix: 3 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Raynaud's Disease (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Southern Illinois University: open-pipeline peers nationwide
Peers matched on 21 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Southern Illinois University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Hologic · 10% recruiting · 21 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
- Corewell Health East · 9% recruiting · 106 trials
- Children's Oncology Group · 10% recruiting · 342 trials
Related
What to do with this Southern Illinois University page
21 registered trials is a research-attention snapshot, not an endorsement of Southern Illinois University or any single study.
- 2 of Southern Illinois University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Raynaud's Disease is the condition Southern Illinois University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Raynaud's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Southern Illinois University pipeline card: 21 registered trials from official public datasets.Report a data error.